Lionbridge Wins Employee Engagement Award from The Conference Board

Lionbridge | July 10, 2019

Lionbridge, the world's most trusted global communications platform, is pleased to announce that it has won the Technology division award for Employee Engagement in the Conference Board's Excellence in Marketing & Communications Awards Program. This prestigious program honors organizations for their innovative use of communications technologies. Last year, Lionbridge developed a new intranet known as The Bridge to help its more than 6,000 employees around the world live out its mission to break barriers and build bridges. The Bridge has supported the change management and transformation of Lionbridge by reenergizing and reengaging the global "Pride." It has created a direct feedback loop between senior management and a global workforce and improved communication and collaboration across departments and countries. "Each year, we highlight how organizations across different industries have achieved their goals through their integration of innovative technologies into their communications and marketing strategies," said Jen McClure, Principal Distinguished Fellow at The Conference Board's Marketing & Communications Center, and Chair of the Center's awards program. "We are very pleased to honor and showcase the pioneering work of Lionbridge as part of this year's awards program."

Spotlight

Welcome to Pharmaprojects’ 2021 review of trends
in pharmaceutical R&D. For almost 30 years now,
I’ve been taking an annual look at the evolution
of pharma R&D, and in this article I’ll examine
the state of play at the start of 2021.


Other News
PHARMACY MARKET

MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

MediPharm Labs Corp. | February 24, 2022

MediPharm Labs Corp. a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug opportunity is predicted to be over USD$25 billion by 2025, and there are over 20 strong novel cannabinoid-based drugs currently in the late-stage research process. These projects will all require pharmaceutical approved API if commercialized. MediPharm has already shipped good manufacturing practice ("GMP") CBD for development purposes to multiple established pharmaceutical companies. "The filing of a US DMF further advances MediPharm toward its ultimate objective of becoming a dominant supplier of API to pharmaceutical companies. This is a high value, high margin opportunity, and with the only purpose-built facility in North America to receive a domestic GMP licence specifically for the extraction of natural cannabinoids, MediPharm is positioned to capture share in this growing market. In the short to medium term, the DMF unlocks new sales channels and will enable us to further leverage the investments made to date on our high-quality pharmaceutical manufacturing platform. Over the longer-term, it ensures the Company is positioned as the go-to cannabinoid partner for pharmaceutical companies around the world." Bryan Howcroft, CEO, MediPharm About MediPharm Labs Founded in 2015, MediPharm specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, API and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines for delivery of pure, trusted and precision-dosed cannabis products for its customers. Through its wholesale and white label platforms, MediPharm formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets.

Read More

BUSINESS INSIGHTS

Virpax Pharmaceuticals Enters Into CRADA With The U.S. Army Institute of Surgical Research

Virpax® Pharmaceuticals, Inc. | May 06, 2022

Virpax® Pharmaceuticals, Inc. a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral indications, today announced that it has entered into a cooperative research and development agreement with the U.S. Army Institute of Surgical Research to evaluate Virpax’s Probudur™, an injectable long-acting liposomal bupivacaine in a hydrogel formulation that is injected at the wound site. Probudur is being developed to significantly reduce or eliminate the need for opioids after surgery in approved indications. Probudur is a local anesthetic that binds to the sodium channel, preventing pain signals from reaching the brain. In pre-clinical trials, Probudur has shown long duration pain control for at least 96 hours. The USAISR is the U.S. Department of Defense’s (DOD) primary laboratory for developing solutions for trauma and critical care challenges in combat casualties. “We are excited to announce this CRADA with the DOD as these military and government research collaborations are an integral part of our non-dilutive funding strategy,” Anthony P. Mack, chairman and CEO of Virpax In August of 2020, Virpax entered into a CRADA with the National Center for Advancing Translational Sciences, an institute of the National Institutes of Health (NIH), for the development of Envelta™, it’s intranasal spray product candidate for severe post-cancer pain and non-cancer pain. Under that agreement, multiple contracts to support the research, development, and manufacturing of Envelta have been awarded by the NIH to continue the product’s progress. About Virpax Pharmaceuticals Virpax is developing branded product candidates for non-addictive pain management and neurological disorders using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval of its three patented drug delivery platforms. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. Probudur™ is a single injection long-acting liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta™ is an intranasal Molecular-Envelope Technology (MET) enkephalin formulation being developed for the management of post-cancer pain and non-cancer pain, as well as post-traumatic stress disorder (PTSD) under the name PES200. MET technology is also used in AnQlar™, Virpax’s product candidate to inhibit viral replication caused by influenza or SARS-CoV-2. Virpax recently acquired global rights to VRP324, a product candidate for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.

Read More

BUSINESS INSIGHTS

Treatment to Expand Global Library of Medicine with Dermatologic Diseases

Treatment.com International Inc. | January 05, 2022

Treatment.com International Inc. a healthcare AI technology company, has entered into a research project agreement with the University of Minnesota to add more than 220 dermatologic diseases to their proprietary, responsive AI engine known as the Global Library of Medicine (GLM). The addition of these diagnoses will bring another level of accuracy and specificity to the GLM, enhancing soon-to-be-released products such as the Treatment Mobile app, which is set for release this month. Kevin A. Peterson, MD, MPH, FRCS(Ed), FAAFP and Chief Medical Officer of Treatment, says, “Engaging in research with the University of Minnesota Dermatology department brings extensive academic medical expertise that enhances our ability to provide richly detailed descriptions of dermatologic concerns. The rich experience of the University of Minnesota Medical School will help the GLM provide more accurate descriptions of complex presentations of skin diseases. Combining our advanced AI infrastructure with the rich clinical and research expertise of the Medical School will substantially enhance our AI platform’s ability to provide better access to high quality information and directly supports the mission of the GLM to enhance health outcomes for individuals around the world.” “We are proud that the University of Minnesota is participating with us on this latest research project, which is in addition to other mutually beneficial agreements we’ve entered into with the University. The Global Library of Medicine is one way we are realizing Treatment’s plan to provide the most accurate and reliable data about health concerns, made available to clinicians, organizations, and patients alike.” John Fraser, Treatment’s CEO The Global Library of Medicine is the foundation of Treatment’s Clinical solutions, which offer unique ways to bring healthcare into the digital age by providing better access to up-to-the-minute healthcare information and promoting better health outcomes around the world. Treatment Mobile and the intelligent digital assistant will be released in select North American clinics in 2022. About Treatment.com Treatment.com is a disruptive healthcare technology company that is harnessing the power of AI to help global citizens improve their health through personalized recommendations and insights. Based in Vancouver with a US subsidiary, the company spent the last five years working with a team of world-class doctors, engineers, mathematicians, and AI specialists to develop a complex AI engine that leverages the most robust, personalized data to generate highly predictive and accurate insights. Treatment.com is the parent company of Treatment Mobile, and an intelligent digital health assistant which will empower people to take control of their health through an innovative mobile app, powered by Treatment’s exclusive AI engine.

Read More

PHARMACY MARKET

Farmacon Global Partners With Validcare for Performance-Based Clinical Research Solutions

Validcare | February 17, 2022

“Validcare’s partnership with Farmacon Global will literally redefine clinical trial success from patient-centric design through database lock,” said Patrick McCarthy CEO Validcare. The Validcare platform accommodates site-based, hybrid and decentralized clinical trials and establishes key performance indicators to ensure study success. “Partnering with Validcare allows our sponsors to quickly identify and implement ROI generating activities like increased patient enrollment and site set up, while facilitating easier communication with principal investigators and on-going participation. This is especially critical for clinical trials in Latin America where Farmacon Global is uniquely positioned for delivering on-time and on-budget studies. Our focus has always been on the voice of the patients enrolled in a study. Today through our Validcare partnership we can offer the empirical results of better access and data integrity with our trial participants through e-CRF, e-diaries and more efficient RWE data being applied at a whole new level,” Tylosky concluded. Sara Tylosky CEO Farmacon Global Validcare will provide critical infrastructure to power Farmacon Global along with relevant metrics and KPIs. “Together, we provide proven processes, tools and technology to overcome the obstacles that typically cause clinical trial delays and failures,” said McCarthy. “We are excited to reset sponsor expectations and execute clinical trials on time and on budget.” About Validcare Founded by experts with more than 20 years of industry experience, Validcare offers the leading solution for best practices in streamlining research for regulatory compliant, life-improving products. Validcare brings a decade of experience powering clinical trials and value-based care models spanning pharma, med device and supplement market segments. About Farmacon Global Farmacon Global is a strategic CRO of medical consultants, providing solutions to accelerate clinical trials in emerging markets – with a specialty in Latin America and emerging markets with in-place medical associates and KOL alliances. Specialties include rare disease, cancer, immunology and infectious disease

Read More

Spotlight

Welcome to Pharmaprojects’ 2021 review of trends
in pharmaceutical R&D. For almost 30 years now,
I’ve been taking an annual look at the evolution
of pharma R&D, and in this article I’ll examine
the state of play at the start of 2021.

Resources